Lavipharm S.A. (ATH:LAVI)

Greece flag Greece · Delayed Price · Currency is EUR
0.832
+0.010 (1.22%)
At close: Dec 5, 2025
14.44%
Market Cap 140.35M
Revenue (ttm) 55.11M
Net Income (ttm) 3.27M
Shares Out 168.69M
EPS (ttm) 0.02
PE Ratio 68.11
Forward PE n/a
Dividend 0.02 (2.43%)
Ex-Dividend Date Jul 17, 2025
Volume 120,029
Average Volume 149,120
Open 0.823
Previous Close 0.822
Day's Range 0.817 - 0.833
52-Week Range 0.650 - 0.912
Beta 0.63
RSI 54.56
Earnings Date Nov 17, 2025

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece. [Read more]

Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Founded 1911
Employees 299
Stock Exchange Athens Stock Exchange
Ticker Symbol LAVI
Full Company Profile

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.

Financial Statements

News

There is no news available yet.